8-K
false000176230300017623032025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): August 12, 2025 |
AVITA Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-39059 |
85-1021707 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
28159 Avenue Stanford Suite 220 |
|
Valencia, California |
|
91355 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 661 367-9170 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share |
|
RCEL |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On August 12, 2025, the Company issued a press release announcing the successful completion of an equity raise in Australia. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
AVITA Medical, Inc |
|
|
|
|
Date: |
August 12, 2025 |
By: |
/s/ David O'Toole |
|
|
|
David O'Toole
Chief Financial Officer |
EX-99.1
Exhibit 99.1
AVITA Medical Successfully Completes Australian Equity Raise
•Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX)
•Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million), with participation from new and existing Australian shareholders
VALENCIA, Calif., August 12, 2025 (being August 13, 2025 in Australia) (GLOBE NEWSWIRE) — AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the successful completion of a private placement (the “Placement”) to institutional and professional investors in Australia to raise an approximate gross amount of US$15 million (approximately A$23 million) by way of the issue of approximately 17.2 million New CDIs at an offer price of A$1.32 per New CDI ("Offer Price").
Proceeds from the Placement will be used for working capital requirements and will provide additional strategic flexibility to support continued growth of the Company’s therapeutic acute wound portfolio. This is expected to cover operations until free cash flow begins in 2026.
“The strong support we received in this Placement reflects growing confidence in our strategy and the transformative potential of our therapeutic acute wound care portfolio,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “We welcome our new Australian shareholders and extend our sincere gratitude to our existing investors for their continued support.”
MST Financial Services Pty Limited acted as sole lead manager.
Placement Details
The Company will issue approximately 17.2 million New CDIs under the Placement at the Offer Price of A$1.32 per New CDI. The Offer Price represents a 11% discount to the last closing price of A$1.48 per CDI on the ASX on Tuesday August 12, 2025, in Australia.
The New CDIs are being issued by the Company in accordance with the Company’s available placement capacity pursuant to ASX Listing Rule 7.1.
The New CDIs are expected to be settled on August 19, 2025, and to be allotted and to commence trading on the ASX shortly thereafter on August 20, 2025. New CDIs issued under the Placement will rank equally with the Company’s existing CDIs on issue.
Indicative Timetable*
|
|
Event |
Date |
Launch of Offer |
Tuesday, August 12, 2025 |
Announcement of completion of Placement |
Wednesday, August 13, 2025 |
Settlement of New CDIs under the Placement |
Tuesday, August 19, 2025 |
Allotment, quotation and trading of New CDIs under the Placement |
Wednesday, August 20, 2025 |
*The above timetable reflects the Australian time zone and the dates may change. AVITA Medical reserves the right to amend these dates at its absolute discretion, subject to the Corporations Act (2001) (Cth), the ASX Listing Rules, and other applicable laws. The quotation of the New CDIs is subject to confirmation from the ASX.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Notice to U.S. persons: restriction on purchasing CDIs
AVITA Medical is incorporated in the State of Delaware and its CDIs have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the laws of any state or other jurisdiction in the United States. Trading of AVITA Medical’s CDIs on the Australian Securities Exchange (the “ASX”) is not subject to the registration requirements of the Securities Act in reliance on Regulation S under the Securities Act, as supplemented by a related “no action” letter issued by the U.S. Securities and Exchange Commission (the “SEC”) to the ASX in 2000. As a result, the CDIs are “restricted securities” (as defined in Rule 144 under the Securities Act) and may not be sold or otherwise transferred except in transactions exempt from, or not subject to, the registration requirements of the Securities Act. To enforce the transfer restrictions, the CDIs will bear a FOR Financial Product designation on the ASX. This designation restricts CDIs from being purchased by U.S. persons. Finally, any hedging transaction with regard to the CDIs may only be conducted in compliance with the Securities Act.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Board of Directors of AVITA Medical, Inc.
